

The Trust. The Truth.

May 02, 2022

To. National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 (Scrip Code: THYROCARE)

BSE Limited Phiroze Jeejeeboy Towers Dalal Street, Mumbai- 400 001 (Scrip Code: 539871)

Dear Sirs/Madam,

Sub: Newspaper Advertisement - Audited financial results for the guarter / year ended 31-03-2022 - pursuant to Regulation 30 and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we have published the Audited financial results for the quarter and Year ended 31 March 2022 in newspapers. We enclose copies of the newspaper advertisement published in Free Press Journal (English) and Pudhari (Marathi).

The above information is also available on the website of the Company www.thyrocare.com. This is for your information and records.

Thanking You,

Yours faithfully,

For Thyrocare Technologies Limited,

Ramjee Dorai

Company Secretary and Compliance Officer

THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703 Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: (91 22) 2762 2762 | Fax: (91 22) 2768 2409 | Website: www.thyrocare.com | E-mail: ramjee.d@thyrocare.com

Corporate Identity Number: L85110MH2000PLC123882



Extract of Audited Consolidated/Standalone Financial Results for the Quarter and Year ended 31 March 2022

(7 in Crorect

											(₹ in Crores)	
Sr. No		Consolidated					Standalone					
		Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended	Year Ended	
		31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.12.2021 (Unaudited)	31.03.2021 (Audited)	31.03.2022 (Audited)	31.03.2021 (Audited)	
1	Total Income from Operations	130.56	117.40	146.84	588.86	494.62	123.33	110.20	139.16	561.53	474.27	
2	Net Profit for the period before tax (before Exceptional and Extraordinary items, share of profit/(loss) of associate)	29.50	28.90	47.45	227.90	152.52	29.38	29.10	47.41	207.38	161.28	
3	Net Profit for the period before tax (after Exceptional and Extraordinary items, share of profit/(loss) of associate)	30.02	28.70	47.63	227.72	152.45	29.38	29.10	47.41	207.38	161.28	
	Net Profit for the period after tax	21.24	21.50	37.75	176.14	113.13	20.35	22.60	35.34	152.05	119.77	
5	Total Comprehensive Income for the period	21.46	21.50	36.36	176.06	111.75	20.51	22.60	33.93	152.01	118.36	
6	Equity Share Capital (Face Value per Share: ₹ 10/- each)	52.90	52.90	52.90	52.90	52.87	52.90	52.90	52.87	52.90	52.87	
7	Other Equity				473.67	374.40						
8	Basic and Diluted Earnings Per Share (of ₹ 10/- each) (not annualised)											
a	Basic:	4.04	4.05	7.14	33.30	21.41	3.86	4.28	6.69	28.75	22.66	
k	Diluted :	4.03	4.05	7.13	33.24	21.37	3.86	4.27	6.68	28.70	22.62	

Notes

- 1 The above financial results of the Company were reviewed and recommended by the audit committee on 29th April 2022 and subsequently approved by the board of directors at its meeting held on 29th April 2022.
- 2 The above is an extract of the detailed format of Consolidated/Standalone Financial Results for the Quarter and Year ended 31st March 2022, filed with the Stock Exchanges under Regulation 47 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Consolidated/Standalone Quarter/Year ended Financial Results are available on the Stock Exchange websites viz. www.nseindia.com. The same is also available on the company's website viz. www.thyrocare.com
- 3 The Board of Directors have declared an interim dividend of Rs.15/- per share for the financial year 2021-22 and fixed 12th May, 2022 as the record date for this purpose.

By Order of the Board For Thyrocare Technologies Limited Dharmil Nirupam Sheth Director DIN: 06999772

Place: Mumbai Date: 29th April, 2022



THYROCARE TECHNOLOGIES LIMITED

Registered Office: D/37-1, TTC industrial Area, MIDC Turbine, Navi Mumbal 400 203 Corporate Office: D/37-3, TTC Industrial Area, MIDC Turbhe, Navi Mumbai 400 703

Tel: 191, 221 2762 2762 | Fax: (9): 222 2768 2409 | Website: www.thwocare.com | E-moil: ramies.di@thwocare.com

Corporate Identity Number: LBS110MH2000PLC129882

Thyrocare*
The Trust. The Truth.

Extract of Audited Consolidated/Standalone Financial Results for the Quarter and Year ended 31 March 2022

	Particulars	Consolidated					Standalione					
Sr. No		Quarter Ended \$1.05.2022 (Factor)	Quarter Ended \$1.32.2021 [Linear/duct]	Quarter Ended \$1.03.2021 (Access)	Year Ended 33.03.2022 Va-Fred	Year Ended	Quarter Ended SL09 2022 (N.e. v.d.	Quarter Ended \$1.12.8821 New field	Quarter Ended 31.05.2021 (A.d ad	Year Ended \$1.05.2022 (Aucket)	Year Ended \$1.05.2021 (4.6'nd)	
1	Total Income from Operations	130.56	117,60	145.64	568,06	494.63	129.11	110.30	139.16	\$61.53	474.27	
2	Not Profit for the period before tax (before Exceptional and Extraordinary Items, share of profit/(linx) of associate)	29.50	28.90	47.45	227.90	352.52	39.38	29,10	45AL	207.88	161.28	
3	Nat Profit for the period before too (after Exceptional and Extraordinary Items, share of profit/(lipss) of associate)	30.02	26.70	47.55	227,72	152.45	25.38	25.10	47.41	207.58	181.28	
4	Nat Profit for the period after too	21.34	21.50	\$7.75	176.14	119.19	30.36	22:60	35.84	152.05	119.77	
5	Total Comprehensive Income for the period	21.44	21.50	36,25	176.06	312.75	30.51	22,90	39.99	192.00	116.96	
6	Equity Share Capital (Face Value per Share: ₹ 10/- each)	52,90	52.00	52:95	13 60	52.87	12.00	52.90	53.87	52.90	53.87	
7	Other Equity				473,67	374.40						
8	Besic and Oliviasi Earnings For Share (of C 10/- each) (not annualized)						A.					
3	Basic :	4.06	4/45	2.14	33.52	21.41	3.80	436	5.60	26.75	22.66	
b	Dilyted:	4.00	4,05	7.13	33,24	21.37	3.85	4.27	5.08	26,70	22.52	

- 1. The above financial results of the Company were reviewed and recommended by the such correct tree on 29th April 2002 and subvey or the population to the country in the first 2002.
- 2 The above is an extract of the detailed format of Consolidated/Spindskine Resource Requiremental Regulations, 2015. The full format of the Constituted/Sunsitive Quarter/Year critical Francial Results are evaluation the Stock Enchange with toxes, were normally one and were to produce the Stock Enchange of the company's which to a rewall-around com-
- 5. The Board of Directors have declared an interim dividend of \$1.25/ per share for the hours, almost \$225.22 and head \$2,25/May, \$202 as the extend date for the squapese.

By-Driber of the Board For Thyrocore Technologies Limited District Mingages Shorts Director DBS DIRECTO